Orlistat for high triglycerides in people with rare genetic lipid conditions
Treatments studied
Part of Hormones & metabolism clinical trials.
This Phase 2 trial studies how well and how safely orlistat works over the long term for people who have very high triglycerides linked to rare genetic lipid disorders. It may help lower triglycerides and assess long-term side effects, but you must meet specific genetic, lab, and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 8 or older
- Have type 1 hyperlipoproteinemia confirmed by genetic testing (or, if not genetically confirmed, still meet the triglyceride level requirement)
- At the end of an 8-week “run-in” period, have fasting triglycerides of at least 750 mg/dL
- If you have diabetes, it must be well controlled (A1c under 8%)
- Agree to avoid orlistat for 2 months before starting, and use pregnancy prevention if you can become pregnant (or prevent pregnancy if you’re a male partner)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests the safety of a gene therapy for people with inherited, hard-to-control high triglycerides (fat in the blood) who have had pancreatitis episodes. It may help by targeting the genes involved in triglyceride control, but the main goal here is to check safety and tolerability.
This trial tests an investigational medication, MAR001, to see if it can lower high levels of fats in the blood (triglycerides and remnant cholesterol) linked to heart disease. If you have these conditions, this treatment might help reduce your risk.
This study tests a new drug, HRS-7249, to see if it safely lowers high triglyceride levels (a type of fat in the blood) that can increase the risk of heart problems. It is for people who either were in the earlier study of this drug or are new participants with high triglycerides.
This study tests a new medicine called DR10624 to see if it can lower very high levels of triglycerides (a type of fat in the blood) in people who have not been helped enough by standard treatments. The study compares the new drug to a placebo (a dummy shot) over several months.
This study tests an investigational medication called DR10624 for people with very high triglycerides, a type of fat in the blood that can increase the risk of heart problems and pancreatitis. The trial aims to see if this drug can safely lower triglycerides better than standard care.
This trial tests a new one-time gene-editing treatment (CS-121) for people with very high triglycerides that don't lower enough with standard medicines. The treatment aims to reduce triglycerides and could help prevent pancreatitis and heart problems, but it is an early-stage gene therapy with strict safety requirements.
Hear when a new Type 1 Hyperlipoprotenemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.